Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Lags Revenue Estimates

Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.1 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to a loss of $1.17 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -12.24%. A quarter ago, it was expected that this company would post a loss of $1.04 per share when it actually produced a loss of $1, delivering a surprise of +3.85%.Over the last four quarters, the company has su ...